Stock Taper
SCREENER COMPARE ANY 2 STOCKS
HRTX
HERON THERAPEUTICS, INC.
NASDAQ
$0.33
▼ DOWN 1.66% (-0.01)

KEY STATISTICS

Market Cap$61.82 M
52w High$1.58
52w Low$0.30
Dividend Yield—
Frequency—
P/E-2.51
Volume949.98K
Shares Out.189.28M

COMPANY

LEADERSHIP

Craig Alexander Collard
CHIEF EXECUTIVE
Craig Alexander Collard

COMPENSATION 2026

Salary$689,431
Stock Awards$946,254
Incentive Plan Pay$517,189
All Other Comp.$10,500
Total$3,516,291

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 26, 1987
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
128

PRICE TARGET

Target High$9.00
Target Low$5.00
Target Median$6.00
Target Consensus$6.67

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$37.50M
NOV
3
TUE

SPLIT RECORD

DATETYPERATIO
2014-01-13Reverse1:20
2007-05-25Reverse1:4

PRICE

$0.33 ▼ DOWN 1.66% (−$0.01)
OVERLAYS
$0.32$0.33$0.33$0.349:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM0.33

About Heron Therapeutics, Inc.

https://www.herontx.com ↗

Heron Therapeutics, Inc. is a biotech company developing innovative drug delivery technologies and treatments, including anti-nausea medications and local anesthetics, to address unmet patient needs.

INDUSTRY

Biotechnology

A PRODUCT HERON THERAPEUTICS, INC. IS KNOWN FOR

ZYNRELEF® (bupivacaine and meloxicam) extended-release solution
ZYNRELEF® (bupivacaine and meloxicam) extended-release solution

ZYNRELEF is a non-opioid, extended-release local anesthetic for postoperative pain up to 72 hours, serving as the company's top revenue contributor in Q4 2025 and emphasizing its focus on the Acute Care franchise.

COMPETITORS

COMPETITOR
COLL COMPARE
PCRX COMPARE
VRPX COMPARE
VRTX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
C I N V A N T I$23.95M $22.92M ▼$20.54M ▼$21.79M ▲
Z Y N R E L E F$9.31M $12.53M ▲$10.23M ▼$11.06M ▲
S U S T O L$1.91M $1.33M ▼$547K ▼$540K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
52
LISTED HERE
9
RANKED BY POSITION SIZE
VTI
0.00% · 5.5M
XSU.TO
0.00% · 3.6M
SCHA
0.00% · 861.9K
ZPRR.DE
0.00% · 242.9K
PRFZ
0.00% · 198.3K
XRSU.L
0.00% · 90.3K
RSSL
0.00% · 75.9K
JF
JFWD
1.78% · 11.6K
URTY
0.00% · 6.5K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
67.86%
HOLDERS
281
TOP 12 OF 281 · RANKED BY POSITION SIZE
Rubric Capital Management LP
30.0M sh · $12.82M
Clearline Capital LP
12.2M sh · $9.79M
Adage Capital Partners Gp, L.L.C.
11.2M sh · $14.54M
Blackrock, Inc.
10.6M sh · $4.5M
Vanguard Group Inc
9.8M sh · $12.77M
Orbimed Advisors LLC
9.8M sh · $7.85M
Velan Capital Investment Management LP
8.8M sh · $7M
Blackrock Inc.
8.3M sh · $29.14M
Millennium Management LLC
7.6M sh · $6.11M
Palisade Capital Management, LP
7.3M sh · $9.23M
Tejara Capital Ltd
6.5M sh · $2.78M
Tang Capital Management LLC
6.3M sh · $2.67M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Ashley Hinson Arenholz
Ashley Hinson Arenholz
Sale (Full)
2021-03-31

INSIDER TRADES

★
OFFICER: CHIEF OPERATING OFFICER
Hensley Mark Earl
Sale · 8.9K shares
2026-08-06
★
OFFICER: CHIEF OPERATING OFFICER
Hensley Mark Earl
Sale · 31.3K shares
2026-08-06
★
OFFICER: CHIEF OPERATING OFFICER
Hensley Mark Earl
Purchase · 31.3K shares
2026-08-06
★
OFFICER: CHIEF OPERATING OFFICER
Hensley Mark Earl
Purchase · 11.8K shares
2026-07-31

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 1
HOLD 1
2 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. NEUTRAL Needham HOLD

SECTORS PEERS

PEERPRICE
SLS$13.21COMPARE
OABI$4.47COMPARE
IVVD$0.96COMPARE
EPRX$6.67COMPARE
CHRS$1.41COMPARE
TARA$3.82COMPARE
MDWD$12.66COMPARE
NTHI$4.69COMPARE